MitoQ Supplementation for Microvascular Health and Stroke Recovery
Key facts
- Who runs it
- Medical College of Wisconsin
- Where
- Milwaukee, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- MitoQ
- Placebo
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age 18-85 years
- Cortical or subcortical stroke ≥ 6 months ago
- Follows 2-step command
- English speaking
Who cannot take part
- Heart attack <1 year ago
- History of other neurological disease
- Other significant medical condition likely to influence study or jeopardize safety as assessed by Primary Investigator
- Unable to walk 10 meters without physical assistance (able to use assistive device)
- Unable to perform HIIE
- Head Trauma < 6 months ago
- Resting BP ≥ 180/100 mmHg
- Pregnant and/or breastfeeding
- Unable to obtain MCAv signal
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Where in United States
- Medical College of WisconsinMilwaukee, United StatesContact: Matthew Durand, PhDNot yet recruiting
About the trial
What the trial wants to find out
Stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. Preliminary data shows an antioxidant supplement called MitoQ may improve vascular function and muscle activity in individuals post-stroke.
The 2 groups in the trial
- Antioxidant Supplement - MitoQTreatment being tested
The investigators will be measuring how an over-the-counter antioxidant supplement, called MitoQ, affects how blood flow responds to movement and exercise. Participants will orally ingest MitoQ during a baseline study visit as well as for 4 weeks at home.
Treatment: MitoQ
- PlaceboPlacebo, for comparison
The investigators will compare the effects of MitoQ to a group receiving a placebo sugar pill. Participants will be randomized into receiving MitoQ or placebo. Participants will orally ingest the placebo pill during a baseline study visit as well as for 4 weeks at home.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07938203, who can take part
- Record updated
- 16 November 2026